BLAINJECTIONINJECTABLE
Approved
Aug 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SKYTROFA (lonapegsomatropin-tcgd) is a recombinant human growth hormone indicated for pediatric growth hormone deficiency. It is administered via subcutaneous injection and works by replacing or supplementing endogenous growth hormone to promote linear growth.
Peak
Product is at peak commercial maturity with moderate competitive pressure (30%), indicating stable market presence and established teams focused on market penetration and retention.
Mechanism of Action
Pharmacologic Class:
Recombinant Human Growth Hormone
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
Started Mar 2023
900 enrolled
Growth Hormone Deficiency
Career Relevance
SKYTROFA roles focus on commercial execution and market defense within the pediatric endocrinology space. Career opportunities center on maintaining market share against competitors and managing payer relationships in a mature growth hormone market.
Brand Manager
Worked on SKYTROFA at Ascend Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.